Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study*): A 12-month, randomized, controlled, double-masked, multicenter phase II study

OBJECTIVE: The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center. RESEARCH DESIGN AND METHODS: This w...

Descripción completa

Detalles Bibliográficos
Autores principales: Massin, Pascale, Bandello, Francesco, Garweg, Justus G., Hansen, Lutz L., Harding, Simon P., Larsen, Michael, Mitchell, Paul, Sharp, Dianne, Wolf-Schnurrbusch, U.E.K., Gekkieva, Margarita, Weichselberger, Andreas, Wolf, Sebastian
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963502/
https://www.ncbi.nlm.nih.gov/pubmed/20980427
http://dx.doi.org/10.2337/dc10-0493

Ejemplares similares

Ejemplares similares